Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CPN1 | P15169 | 2/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.49 |
| ▸ | PBK | Q96KB5 | 5/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768724 | 1.00 | CYP2D6 (0.51) | CYP2D6CPN1CPB2PBKSLC6A1 | |
| SCHEMBL5649078 | 1.00 | CYP2D6 (0.51) | CYP2D6CPN1CPB2PBKSLC6A1 | |
| Hydrochloric Acid SCHEMBL4014842 | 0.98 | CYP2D6 (0.50) | CYP2D6CPN1CPB2PBKSLC6A1 | |
| Hydrochloric Acid SCHEMBL4020092 | 0.98 | CYP2D6 (0.50) | CYP2D6CPN1CPB2PBKSLC6A1 | |
| Hydrochloric Acid SCHEMBL4014839 | 0.98 | CYP2D6 (0.50) | CYP2D6CPN1CPB2PBKSLC6A1 | |
| Oxalic Acid SCHEMBL4020910 | 0.96 | CYP2D6 (0.49) | CYP2D6CPN1CPB2PBKSLC6A1 | |
| Oxalic Acid SCHEMBL4020925 | 0.96 | CYP2D6 (0.49) | CYP2D6CPN1CPB2PBKSLC6A1 | |
| SCHEMBL856745 | 0.89 | SLC6A1 (0.57) | CYP2D6CPN1CPB2SLC6A1SLC6A11 | |
| SCHEMBL2832801 | 0.89 | SLC6A1 (0.57) | CYP2D6CPN1CPB2SLC6A1SLC6A11 | |
| SCHEMBL2836599 | 0.89 | SLC6A1 (0.57) | CYP2D6CPN1CPB2SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-07-18 | — | — | US | disclosed |
| WO-2024151346-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108100-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| EP-4326716-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-02-28 | — | — | EP | disclosed |
| CN-1425008-A | 3-aminoquinazolin-2, 4-dione antibacterial agents | WARNER LAMBERT CO (US) | 2003-06-18 | — | — | CN | disclosed |
| EP-0559046-B1 | N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors | HOFFMANN LA ROCHE (CH) | 2001-07-11 | — | — | EP | disclosed |
| US-5763604-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5677448-A | CHEMICAL INTERMEDIATES FOR MAKING ANTAGONIST OF THROMBIN, TREATING THROMBOSIS, STROKE, INFLAMMATION, ARTERIOSCLEROSIS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5578594-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0520882-B1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1995-07-12 | — | — | EP | disclosed |
| US-5405854-A | Anticoagulants | HOFFMANN-LA ROCHE INC. (US) | 1995-04-11 | — | — | US | disclosed |
| EP-0559046-A1 | N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1993-09-08 | — | — | EP | disclosed |
| EP-0522914-A1 | 2-Piperidinylpyrimidin-4-carboxamide derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1993-01-13 | — | — | EP | disclosed |
| EP-0520882-A1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | CYP2D6 3452/4885CPN1 4336/4885CPB2 4747/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | CYP2D6 873/4885CPN1 4218/4885CPB2 3642/4885 |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | SIGMAR1, TMEM97, OPRD1 | CYP2D6 193/4885CPN1 3928/4885CPB2 4647/4885 |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | DGKA, DGKG, DGKK | CYP2D6 2446/4885CPN1 3984/4885CPB2 3113/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | CYP2D6 1832/4885CPN1 1431/4885CPB2 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.